The US Landscape and the Regulatory Bottleneck in PTCL

Brammer describes a US treatment landscape that mirrors the European experience, with poor outcomes for patients whose peripheral T-cell lymphoma has relapsed or become refractory. He reviews the modestly effective tools available, including standard chemotherapies, B-cell–derived regimens, and agents such as romidepsin and pralatrexate, each carrying only limited response rates and, in the case of pralatrexate, meaningful toxicity that can be difficult to manage outside academic centers. Brammer notes that the overarching goal often remains bridging patients to transplant, though rapid progression frequently makes that impossible. Both experts discuss how the rarity of these diseases has historically complicated randomized trial design and regulatory approval, with agencies requiring phase 3 evidence that is hard to generate. Brammer contrasts the situation with B-cell lymphoma, where novel immunotherapies have flourished, observing that in T-cell lymphoma the histone deacetylase inhibitors represent one of the few genuinely new classes to emerge.